NRXP vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

NRXP

57.1
AI Score
VS
NRXP Wins

CBIO

45.7
AI Score

Investment Advisor Scores

NRXP

57score
Recommendation
HOLD

CBIO

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric NRXP CBIO Winner
Revenue 1.07M 1.04M NRXP
Net Income -1.43M -48.12M NRXP
Net Margin -133.9% -4631.4% NRXP
Operating Income -4.74M -51.09M NRXP
ROE 10.4% -29.5% NRXP
ROA -12.0% -26.3% NRXP
Total Assets 11.90M 182.76M CBIO
Cash 6.71M 171.59M CBIO
Current Ratio 0.29 9.66 CBIO

Relative Price Performance (Last 90 Days)

NRXP 1M: -18.4% · 3M: +5.7% CBIO 1M: -15.3% · 3M: -35.3%

Current Technical Phase

NRXP

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 33

RSI (14): 33.1 · Price: $3.15

CBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.7%), weak momentum, RSI 39

RSI (14): 38.5 · Price: $14.47

Fundamentals Snapshot

Metric NRXP CBIO
Market Cap
Forward P/E 6.3 -4.9
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 0.5% 1.0%
Operating Margin -4.4% -23.8%
EPS -1.00 -5.97
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, NRXP is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.